Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Banyu Pharmaceutical was a prominent Japanese pharmaceutical company that served as the primary vehicle for Merck & Co. (MSD) in Japan for several decades. Founded in 1915, the company established a landmark partnership with Merck in the 1950s, leading to Merck acquiring a majority stake in 1984 and full ownership in 2004. Banyu was instrumental in the Japanese development and commercialization of global blockbuster therapies, particularly in the fields of cardiovascular health, metabolic disorders, and infectious diseases. In 2010, following the global merger of Merck and Schering-Plough, Banyu merged with Schering-Plough's Japanese operations to form MSD K.K. Today, its legacy continues through the extensive portfolio of medicines and vaccines distributed by MSD in the Japanese market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Banyu Pharmaceutical.